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 To the Editor, 
 The use of creatinine (Scr) for estimates of glomerular fil-
tration rate (GFR) in neonates is hampered by both physi-
ologic fluctuations and analytic aspects [1 – 5]. Postnatal 
life is characterized by a Scr rise, most pronounced in the 
most immature neonates, followed by a decrease, slowest 
in the most immature [1, 2]. Besides perinatal physiologic 
fluctuations, measurements also depend on the quantifi-
cation method [3 – 5]. Initially, Scr reference values were 
based on uncompensated Jaffe, a colorimetric reaction 
using alkaline picrate. Jaffe assays suffer from interference 
by endogenous (e.g., pseudocreatinines, hemoglobin F, 
IgG, bilirubin) and exogenous (e.g., cephalosporins) sub-
stances commonly retrieved in neonatal samples [3 – 5]. 
More recently, enzymatic methods were introduced. These 
assays are less prone to such interferences and thus more 
suitable in neonates. Nevertheless, enzymatic assays can 
also be affected by interferences (e.g., bilirubin, dopa-
mine) [3 – 7]. It is generally accepted that uncompensated 
Jaffe overestimates Scr and fixed corrections (e.g., 0.2 or 
0.3 mg/dL) or adaptations in the analytical procedure 
(e.g., rate blanking) have been suggested to adapt Jaffe 
assays observations [3 – 7]. To illustrate the limitations of 
any fixed correction, postnatal age-related between assay 
differences in the mean reference Scr values of uncom-
pensated Jaffe or enzymatic Scr in two consecutive cohorts 
(2000 – 2005 vs. 2007 – 2010) of extreme preterm neonates 
varied between 0.12 and 0.27 mg/dL [2]. 
 The Scr standardization program was created by the 
National Kidney Disease Education Program to reduce 
assay variation [6]. Jaffe and enzymatic quantification 
methods were calibrated to isotope dilution mass spec-
trometry (IDMS). We hypothesized that the IDMS-based 
Scr standardization program affects the extent of the 
remaining between assay Scr differences. To explore this 
and its covariates in neonates, Scr values measured by 
Jaffe and enzymatic methods in the same serum samples 
were compared. 
 Following approval (B322201214963, UZ Leuven, 
Belgium) and informed written parental consent, an addi-
tional blood sample (0.6 mL) was collected when sampling 
was performed for clinical indication. Each newborn was 
only included once. Samples were centrifuged (Eppendorf 
centrifuge 5415R, room temperature, 5 min, 5000 rpm, 
equal to 2320  g ) and serum was subsequently divided in 
two containers and stored ( − 80 ° C) until analysis. Clinical 
characteristics [gestational age, postnatal age, postmen-
strual age, birth weight, current weight, co-administration 
amoxicillin, co-administration dopamine, packed cells 
transfusion during neonatal stay before sampling, biliru-
bin (total, direct), and albumin] were registered. This list 
was based on the literature on in vitro interferences as 
described for creatinine assays and on the compounds 
prescribed [8]. Samples were analyzed by a Jaffe and an 
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enzymatic method, using methods currently available in 
the University Hospitals Leuven (i.e., Roche Diagnostics 
compensated Jaffe and enzymatic method, both IDMS 
traceable, measured on Cobas c702 module). Albumin 
and bilirubin (total and direct) were measured by bro-
mocresol green and diazo colorimetric assays, respec-
tively (Roche Diagnostics, Cobas c702 module). Clinical 
characteristics and bio-analytical results were described, 
regression and Bland-Altman analysis were performed 
to explore differences between both measurements and 
trends in its variability. Paired analysis (Wilcoxon) was 
performed to quantify differences between both analyses, 
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 Figure 1   A significant correlation (rho = − 0.52, 95% CI  − 0.67 to  − 0.32, p < 0.0001) between total bilirubin and the absolute difference (Jaffe –
 enzymatic, mg/dL) in serum creatinine between both assays was observed. 
 Table 1   Clinical characteristics. Data provided by median and 
range, mean and standard deviation or incidence. 
 Gestational age (GA), weeks  38 (range 24 – 41) 
 Postnatal age, days  3 (range 0 – 236) 
 Postmenstrual age, weeks  39 (range 26 – 75) 
 Current weight, g  3190 (range 625 – 4550) 
 Preterm,  < 37 weeks GA  33% 
 Extreme preterm,  < 32 weeks GA  18% 
 Co-treated amoxicillin  11% 
 Co-treated dopamine  0% 
 Received packed cells transfusion  18% 
 Albumin, g/L  34.7 (SD 6.24) 
 Bilirubin, total, mg/dL  6.8 (SD 4.55) 
 Bilirubin, direct, mg/dL  0.53 (range 0.18 – 2.42) 
 Creatinine, Jaffe, mg/dL  0.50 (range 0.17 – 1.16) 
 Creatinine, enzymatic, mg/dL  0.49 (range 0.06 – 1.11) 
 Difference (Jaffe  – enzymatic), mg/dL  0.013 (range  − 0.2 to 0.11) 
and covariates of differences were explored (Rank correla-
tion, Mann-Whitney U, linear regression). 
 Samples were collected in 129 neonates and young 
infants. Clinical characteristics and Scr values are pro-
vided in  Table 1 . A significant relationship between 
both Scr measurements was documented (r 2 = 0.9487, 
y = 0.0038 + 0.967x, p < 0.001). Bland-Altman analysis illus-
trates that there is no Scr concentration-related impact on 
this difference. The mean difference between both assays 
is 3.9%. In contrast, bilirubin (total, direct) had a signifi-
cant effect on the difference between both assays (total 
bilirubin, p < 0.0001). Jaffe creatinine was proportionally 
lower when compared to enzymatic measurement in the 
setting of elevated bilirubin ( Figure 1 ). Similarly, a sig-
nificant effect of albumin on the between assay difference 
was documented (p = 0.0016). In a multiple regression 
model, only total bilirubin remained significant (r 2 = 0.24, 
p < 0.001). 
 In essence, a statistical significant (p = 0.0039) but 
clinical likely not very relevant mean difference of 0.013 
mg/dL between IDMS traceable Jaffe and enzymatic assays 
was documented, and the extent of the difference was in 
part explained by bilirubin. There are several reports that 
illustrate that Jaffe as well as enzymatic measurements are 
affected by bilirubin, although interference of enzymatic 
methods has been minimized [7 – 9]. Hyperbilirubinemia 
(unconjugated) is common, because of age-related matu-
ration of glucuronidation [10]. In the current study, rising 
bilirubin (up to 16.1 mg/dL) resulted in relatively lower (up 
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to 0.1 mg/dL) Jaffe Scr values compared to enzymatic meas-
urements ( Figure 1 ). This is likely explained by overcorrec-
tion of the Jaffe assay. Bilirubin interference is caused by 
an oxidation of bilirubin to biliverdin in the alkaline Jaffe 
reaction medium. The Roche Jaffe assay uses rate-blank-
ing to compensate for this interference. Prior to adding 
picric acid (and starting the reaction), alkaline is added 
to the sample, the bilirubin oxidation rate is measured 
and later on subtracted from the measured reaction rate 
of creatinine with alkaline picric acid. As the oxidation 
of bilirubin in alkaline is curvilinear, overcorrection can 
occur with increasing bilirubin. These observations are in 
agreement with the findings of Roche. Significant interfer-
ence is excluded up to 10 mg/dL unconjugated bilirubin 
for the Jaffe and up to 20 mg/dL for the enzymatic assay. In 
clinical laboratory practice, Jaffe creatinine results from 
samples with high bilirubin concentrations ( > 10 mg/dL) 
should not be reported or a warning should be added. In 
addition, we confirmed an albumin concentration related 
effect on the difference between both assays, although the 
impact is more limited when compared to bilirubin. We 
initially aimed to compare both observations to a  ‘ gold ’ 
standard reference for creatinine like high performance 
liquid chromatography (HPLC) or mass spectrometry. 
Unfortunately, because of insufficient remaining sample 
volumes, this was not feasible. Consequently, we can only 
describe differences between both assays used, and are 
unable to make suggestions on how these assays relate 
to such a gold standard or how other Jaffe or enzymatic 
assays relate to these findings [7]. Other limitations may 
be the absence of patients with very high bilirubin ( > 16 
mg/dL), and the limited number of cases exposed to co-
medication (antibiotics, inotropics). 
 Taking these limitations into account, differences 
between IDMS traceable Jaffe and enzymatic assays were 
limited, even in a heterogeneous group of neonates with 
still an assay-specific impact of bilirubin. 
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